MARLBOROUGH, Mass., April 28, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials for dermal scarring and subretinal fibrosis associated with late stage AMD. Topical administration to the eye of the Company's novel self-delivering RNAi (sd-rxRNA®) technology formulated in a gel resulted in delivery throughout the cornea in the presence of a corneal wound in vivo.
"These findings further highlight the utility of our sd-rxRNA platform and provide evidence of the potential development of topical oligonucleotide based therapeutics for front of the eye indications," said Pamela Pavco, Ph.D., RXi's Chief Development Officer. She further added, "We know that corneal wounds can lead to scar formation and impaired vision. These data broaden the market potential for RXI-109 and open new avenues for collaboration."
As previously released, this data will be presented at ARVO on Sunday, May 1, 2016 and the poster will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA®) Platform
Building on the pioneering work of Dr. Craig Mello, Nobel Laureate and RXi's Scientific Advisory Board Chairman, scientists at RXi developed novel sd-rxRNA compounds where drug-like properties are built into the RNAi compound itself. These proprietary compounds are novel RNAi compounds with enhanced properties for therapeutic use including: efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity. All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing. Efficient cellular uptake is observed both in vitro and in vivo, including into tissues such as skin and retina following local administration, and liver following systemic delivery. RXI-109, an sd-rxRNA compound is designed to silence connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair. RXI-109 is currently being evaluated in two clinical trials. A Phase 1/2 clinical study, RXI-109-1501, is underway to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. In addition, a Phase 2 clinical trial, RXI-109-1402, is currently evaluating RXI-109 as a treatment to reduce the recurrence of hypertrophic scars following scar revision surgery. Over 100 subjects have been treated with RXI-109 by intradermal injection in all trials to date. Multiple intradermal injections were well tolerated at all dose levels. RXI-109 was shown to cause a dose-dependent silencing of CTGF messenger RNA and protein levels in the treated areas of the skin compared to placebo and preliminary results from Phase 2a studies indicate a clinical effect on scar appearance.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.